Introduction: The "Four-Hour" Threshold Under Fire
For decades, the standard of care for obstructive sleep apnea (OSA) has been dictated by a rigid numerical benchmark. Under current Centers for Medicare and Medicaid Services (CMS) policy, patients diagnosed with OSA must demonstrate “adherence” by using their continuous positive airway pressure (CPAP) machines for at least four hours a night on 70% of nights within a 30-day window during their first 90 days of treatment. Failure to hit this specific metric often results in the revocation of insurance coverage, effectively forcing the patient to either pay out-of-pocket or abandon therapy entirely.
However, a groundbreaking study presented at the American Thoracic Society (ATS) 2026 conference suggests that this "one-size-fits-all" approach may be systematically depriving thousands of patients of life-saving care. The data indicates that early struggles with CPAP devices are not necessarily indicative of long-term failure, challenging the clinical and bureaucratic foundations of current insurance coverage policies.
Main Facts: The Kaiser Permanente Insight
The research, led by Dr. Dennis Hwang, a prominent sleep and pulmonary physician at Kaiser Permanente Southern California, offers a rare, large-scale look at what happens when the strictures of CMS policy are removed.
By analyzing data from over 132,000 patients within the Kaiser Permanente network—a system that, unlike many others, continues to provide CPAP devices to patients regardless of whether they meet the CMS early-use threshold—researchers were able to observe the natural trajectory of CPAP usage.
The primary findings are as follows:
- Widespread Initial Non-adherence: A staggering 51% of patients failed to meet the CMS 90-day adherence criteria.
- The "Slow-Starter" Phenomenon: More than one-third (over 33%) of those who were deemed "non-adherent" by Medicare standards were still using their CPAP devices consistently one year later.
- Clinical Efficacy at Lower Usage: Patients who fell short of the four-hour threshold were often still utilizing their devices for at least two hours per night. Medical evidence suggests this level of usage is sufficient to provide symptomatic relief, effectively debunking the idea that any usage below the CMS threshold is a failure.
Chronology: The Evolution of the 90-Day Rule
To understand the implications of Dr. Hwang’s findings, one must look at the history of the "90-day rule."
- The Early 2000s: As CPAP therapy became the gold standard for OSA, insurance providers, led by CMS, sought to mitigate costs by ensuring that expensive medical equipment was actually being utilized. The "four-hour/70%" rule was adopted as a proxy for clinical success.
- The Mid-2010s: Sleep medicine clinicians began voicing concerns that the threshold was arbitrary. Critics argued that the transition to PAP therapy is notoriously difficult, requiring patients to adjust to facial masks, pressure settings, and the psychological hurdle of sleeping with a machine.
- The COVID-19 Era: The pandemic introduced significant disruptions to sleep medicine, including supply chain issues for CPAP devices and limited access to in-person clinical coaching, further highlighting the volatility of early adherence.
- May 2026: At the ATS 2026 conference (Presentation D97), the Kaiser Permanente study was unveiled, providing the most robust empirical evidence to date that the 90-day requirement does not accurately predict long-term treatment success.
Supporting Data: Understanding the Patient Experience
The study’s most compelling aspect is the scale of the population involved. By tracking 132,000 patients, Dr. Hwang’s team bypassed the limitations of smaller, hospital-based studies that often suffer from selection bias.
Why Patients Struggle Early
The data supports the clinical observation that the first 90 days are a period of high friction. Factors contributing to early non-adherence include:
- Mask Intolerance: Physical discomfort or air leaks during the learning phase.
- Psychological Barriers: The transition to "sleeping with a machine" requires significant lifestyle adaptation.
- Variable Symptoms: Some patients with milder OSA symptoms may not immediately perceive the dramatic health benefits of the machine, leading to decreased motivation during the first month.
The "Two-Hour" Benefit
The study highlights that even two hours of usage—half of the CMS mandate—significantly reduces daytime sleepiness and improves cognitive function. By stripping away insurance coverage because a patient only averages 2.5 hours instead of four, the current policy effectively denies these patients the incremental health benefits they have already begun to realize.
Official Responses and Clinical Perspectives
The medical community has reacted with significant interest to the presentation, titled "When Treatment Meets Reality: Outcomes, Adherence, and Policy in Sleep Apnea Management."
"Our findings suggest clinicians and policymakers should not rely solely on Medicare-defined adherence, given its reliance on early CPAP use and an arbitrary four-hour threshold, when making long-term treatment decisions," Dr. Hwang stated during the session.
Dr. Hwang’s position is echoed by many in the sleep medicine field who advocate for "personalized adherence targets." Rather than a binary "pass/fail" metric, these experts suggest that clinical success should be measured by patient-reported outcomes—such as reductions in blood pressure, improvements in daytime alertness, and the mitigation of morning headaches—rather than a static usage timer.
Advocacy groups for sleep disorders have long argued that the 90-day rule is a "cost-saving measure disguised as a clinical standard." By forcing providers to stop providing equipment, the policy shifts the burden of cost to the patient or, more often, leads to the abandonment of treatment, which results in higher long-term healthcare costs due to cardiovascular complications, stroke, and hypertension linked to untreated OSA.
Implications: The Future of Sleep Medicine Policy
The implications of the Kaiser Permanente data are far-reaching and suggest a need for a fundamental shift in how insurance companies approach chronic disease management.
1. Reforming Coverage Policies
Policymakers, specifically those at CMS, are now under increased pressure to evaluate whether the 90-day threshold remains scientifically defensible. If one-third of "non-adherent" patients are actually long-term users, the current policy is essentially punishing patients who simply need more time to adapt.
2. The Role of Tele-Health and Remote Monitoring
The study suggests that instead of cutting off coverage, the healthcare system should invest in "extended support" programs. Using the data from the study, healthcare providers could identify "slow-starters" in the first 30 days and provide targeted interventions—such as mask refittings, additional education, or tele-health check-ins—to help those patients cross the finish line.
3. A Shift Toward Patient-Centered Metrics
Future research, as outlined by Dr. Hwang’s team, will focus on identifying the profiles of patients most likely to succeed in the long term despite early struggles. By shifting the focus from "usage time" to "clinical outcome," the medical community can create a more inclusive and effective treatment pathway.
4. Economic Consequences
While insurance providers are wary of the costs associated with continuous CPAP coverage, the long-term economic argument is shifting. Treating the consequences of untreated OSA—such as heart disease and stroke—is exponentially more expensive than providing a CPAP machine and the necessary coaching to ensure its use.
Conclusion: Moving Beyond the Threshold
The findings presented at ATS 2026 serve as a wake-up call for the sleep medicine industry. The reliance on an arbitrary, early-use threshold like the four-hour Medicare rule is not only scientifically questionable but also potentially harmful to patient health.
As the healthcare system continues to evolve, the focus must shift from rigid, box-ticking compliance to sustainable, long-term patient engagement. If the goal is to improve the health of those suffering from obstructive sleep apnea, the "fail-first" mentality regarding device coverage must be abandoned in favor of a model that acknowledges the reality of the patient journey: that recovery is a process, not a race.
The next steps for the research team—evaluating how to better support these "slow-start" patients—will be critical in informing the next generation of healthcare policy. Until then, the message to clinicians is clear: do not let a 90-day data point dictate the end of a patient’s path to better sleep and better health.
Summary of Key Takeaways
- The Data: 51% of patients do not meet the 90-day CMS threshold, yet over 33% of those individuals remain consistent users one year later.
- The Clinical Reality: Two hours of usage provides tangible health benefits, contradicting the necessity of the 4-hour mandate.
- The Policy Gap: Current Medicare rules prioritize administrative benchmarks over patient-centered outcomes, leading to unnecessary therapy discontinuation.
- The Path Forward: The focus should transition from punitive coverage policies to supportive, outcome-based clinical management that helps patients adapt to therapy at their own pace.
